Iodine-131 Tositumomab(Bexxar) in relapsed/refractory non-Hodgkin's lymphoma: update from the 2001 American Society of Hematology meeting.
Gibson
Angelia
A
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D003226:Congresses as Topic; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D012955:Societies, Medical; D015996:Survival Rate; D016896:Treatment Outcome; D014481:United States
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; C119496:tositumomab I-131